MetLife Investment Management’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $535K | Sell |
996
-8,304
| -89% | -$4.25M | ﹤0.01% | 1874 |
|
|
2026
Q1 | $4.87M | Sell |
9,300
-937
| -9% | -$448K | 0.02% | 623 |
|
|
2025
Q4 | $5.96M | Sell |
10,237
-570
| -5% | -$291K | 0.03% | 547 |
|
|
2025
Q3 | $4.96M | Buy |
10,807
+745
| +7% | +$278K | 0.02% | 637 |
|
|
2025
Q2 | $3.05M | Sell |
10,062
-391
| -4% | -$116K | 0.02% | 790 |
|
|
2025
Q1 | $3.46M | Sell |
10,453
-365
| -3% | -$120K | 0.02% | 796 |
|
|
2024
Q4 | $3.34M | Buy |
10,818
+695
| +7% | +$195K | 0.02% | 782 |
|
|
2024
Q3 | $2.15M | Hold |
10,123
| – | – | 0.01% | 982 |
|
|
2024
Q2 | $2.84M | Buy |
10,123
+2,537
| +33% | +$604K | 0.02% | 811 |
|
|
2024
Q1 | $2.03M | Sell |
7,586
-172
| -2% | -$40.5K | 0.01% | 942 |
|
|
2023
Q4 | $1.8M | Buy |
7,758
+581
| +8% | +$102K | 0.01% | 988 |
|
|
2023
Q3 | $1.05M | Hold |
7,177
| – | – | 0.01% | 1204 |
|
|
2023
Q2 | $1.66M | Buy |
7,177
+495
| +7% | +$134K | 0.01% | 1007 |
|
|
2023
Q1 | $1.62M | Hold |
6,682
| – | – | 0.01% | 991 |
|
|
2022
Q4 | $1.94M | Hold |
6,682
| – | – | 0.01% | 920 |
|
|
2022
Q3 | $434K | Hold |
6,682
| – | – | ﹤0.01% | 1743 |
|
|
2022
Q2 | $478K | Hold |
6,682
| – | – | ﹤0.01% | 1700 |
|
|
2022
Q1 | $656K | Buy |
6,682
+2,468
| +59% | +$208K | ﹤0.01% | 1610 |
|
|
2021
Q4 | $357K | Buy |
4,214
+527
| +14% | +$43.3K | ﹤0.01% | 1693 |
|
|
2021
Q3 | $294K | Hold |
3,687
| – | – | ﹤0.01% | 1831 |
|
|
2021
Q2 | $359K | Hold |
3,687
| – | – | ﹤0.01% | 1776 |
|
|
2021
Q1 | $431K | Hold |
3,687
| – | – | ﹤0.01% | 1616 |
|
|
2020
Q4 | $410K | Hold |
3,687
| – | – | ﹤0.01% | 1586 |
|
|
2020
Q3 | $438K | Hold |
3,687
| – | – | ﹤0.01% | 1434 |
|
|
2020
Q2 | $418K | Hold |
3,687
| – | – | ﹤0.01% | 1484 |
|
|
2020
Q1 | $246K | Hold |
3,687
| – | – | ﹤0.01% | 1580 |
|
|
2019
Q4 | $336K | Hold |
3,687
| – | – | ﹤0.01% | 1672 |
|
|
2019
Q3 | $318K | Hold |
3,687
| – | – | ﹤0.01% | 1676 |
|
|
2019
Q2 | $386K | Sell |
3,687
-5,682
| -61% | -$609K | ﹤0.01% | 1630 |
|
|
2019
Q1 | $1.17M | Buy |
9,369
+6,246
| +200% | +$776K | ﹤0.01% | 1568 |
|
|
2018
Q4 | $352K | Hold |
3,123
| – | – | ﹤0.01% | 1582 |
|
|
2018
Q3 | $669K | Buy |
3,123
+422
| +16% | +$106K | 0.01% | 1349 |
|
|
2018
Q2 | $755K | Buy |
2,701
+586
| +28% | +$103K | 0.01% | 1164 |
|
|
2018
Q1 | $247K | Hold |
2,115
| – | – | ﹤0.01% | 1774 |
|
|
2017
Q4 | $194K | Buy |
+2,115
| New | +$121K | ﹤0.01% | 1943 |
|
Other funds holding MDGL
BBA
RI
JT
ACA
PC
MetLife Investment Management's MDGL Position: Q2 2026 in Review
MetLife Investment Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 89% in Q2 2026, selling an estimated $4.25M and leaving 996 shares worth $535K. The position accounts for ﹤0.01% of the portfolio, ranked #1874.
MetLife Investment Management first reported a position in MDGL in Q4 2017 and has held it in 35 quarters since. The position peaked at $5.96M in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.
- MetLife Investment Management held 996 shares of Madrigal Pharmaceuticals worth $535K as of Q2 2026.
- MetLife Investment Management sold 8,304 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $4.25M.
- Madrigal Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1874 holding.
- MetLife Investment Management first reported a position in Madrigal Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
- MetLife Investment Management's Madrigal Pharmaceuticals position peaked at $5.96M in Q4 2025.
- 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.